CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome Twenty participants ...

Fratricide-resistant CD7 CAR-T therapy by NUS proves effective in treating relapsed or refractory T-cell leukaemia A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...

A study has demonstrated the potential of a novel ligand-based CAR T-cell therapy for targeting CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell ...

Infusion of base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia enabled 82% of patients in a phase I study to achieve a deep remission after receiving the therapy, allowing them to ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in ...

-- First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy to Begin in First Quarter 2025 -- The Global Study Will Evaluate WU-CART-007 in Pediatric and Adult Patients ST.